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Background: Women often lag behind men in their risk of cardiovascular events. However, with age and the onset
of menopause, women’s cardiovascular risk eventually becomes similar to that of men. This change in risk may, in
part, be attributable to a shift to a more atherogenic lipid profile. Our objective was to evaluate standard- and
sub-lipid parameters and the apo A1 remnant ratio: (apo A1/[VLDL3-C+IDL-C]) for their associations with death/
myocardial infarction among peri- and post-menopausal women.
Methods: Women (N=711) >50 years of age undergoing coronary angiography were evaluated. Baseline clinical
and angiographic characteristics, lipids, and sub-lipid levels (Vertical Auto Profile method) were collected. Cox
regression analysis, adjusted by standard cardiovascular risk factors, was utilized to determine associations of lipid
and sub-lipid tertiles(T) with death/myocardial infarction at 1 and 3 years.
Results: Patients averaged 67.7±9.4 years and 53.6% had underlying severe (≥70% stenosis) coronary artery disease.
The apo A1 remnant ratio was found to have stronger associations for 1 year (T1 vs. T3: HR=2.13, p=0.03, T2 vs. T3:
HR=1.57, p=0.21) and 3 year (T1 vs. T3: HR=2.32, p=0.002, T2 vs. T3: HR=1.97, p=0.01) death/myocardial infarction
than any individual lipid (LDL-C, HDL-C, triglycerides, non-HDL-C) or sub-lipid (apo A1, apo B, VLDL3-C+IDL-C)
measure, or any other well-known ratio (triglyercies/HDL-C, apo B/A1, TChol/HDL-C, HDL-C/[VLDL3-C+IDL-C]).
Conclusions: The apo A1 remnant ratio was a significant predictor of short and intermediate-term death/
myocardial infarction risk among women >50 years of age. Furthermore, this ratio was found to have greater
predictive ability than traditional lipid and sub-lipid parameters and represents a potential new risk marker.
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Metabolic Syndrome 31.2% (222)
Family history of coronary artery disease 42.3% (301)
Smoking 12.7% (90)
Renal failure 1.0% (7)
Heart failure 0.8% (6)
Prior myocardial infarction 5.8% (41)
Prior cerebrovascular accident 4.6% (33)
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Coronary heart disease (CHD) is the leading cause of death
among men and women, although the risk in women tem-
porally lags behind that of men (1). Nevertheless, the
median survival for a woman age 55 to 64 with a first myo-
cardial infarction (MI) is only 13.3 years compared to 17
years for a man [1]. Furthermore, for women aged 65 to 74
this median survival decreases to only 8.8 years [1]. Also,
64% of women who die suddenly of CHD have no previous
symptoms compared to 50% for men. While most CHD
risk factors are similar between men and women, they can
often vary in strength and association and change through-
out the lifetime [2,3]. This is especially evident for lipids,
with low high-density lipoprotein cholesterol (HDL-C)
cholesterol and hypertriglyceridemia being stronger predic-
tors of CHD in women than in men [4-6]. Also, with age
and the onset of menopause, women’s lipoprotein profile
becomes more atherogenic [3], which is associated with a
rapid increase in cardiovascular risk. However, how to best
quantify cardiovascular risk in women incorporating lipid
parameters is unclear.
While low-density lipoprotein cholesterol (LDL-C), an
atherogenic lipoprotein, has been recognized as the
target of lipid lowering therapy, it is not always indica-
tive of atherogenicity. Other lipoprotein parameters (i.e.,
remnant lipoproteins) have been shown to be more
atherogenic, particularly in women, including apolipopro-
tein (apo) B, intermediate-density lipoprotein cholesterol
(IDL-C), and subfractions of very low-density lipoprotein
cholesterol (VLDL-C) [7-11]. In addition, the triglyceride
to HDL-C ratio (TG/HDL-C) has been shown to be an
atherogenic marker [12] and a powerful independent pre-
dictor of all cause mortality and cardiovascular events
among postmenopausal women [13] and men [14,15].
Gofman et al. first reported over 60 years ago that rem-
nant lipoproteins were associated with the development of
CHD [16]. Remnant lipoproteins have been shown to be el-
evated in patients with the metabolic syndrome [17], im-
paired glucose tolerance, and type 2 diabetes mellitus [18].
Remnant lipoproteins have also been reported to predict
the extent of angiographically defined coronary artery dis-
ease (CAD) in post-menopausal women [19] and predict
coronary events in patients with CAD [20,21].
It is well recognized that HDL-C has a strong inverse
association with adverse CHD events among women.
However, clinical events continue to occur even in pa-
tients who achieve “target” levels. The Framingham Heart
Study reported that 43% of clinical events occurred in
women with an HDL-C ≥50 mg/dL [6]. Also, apo A1, the
major component of HDL, has been shown to predict
short-term and long-term risk in patients with normal
HDL-C [22]. This finding indicates that just measuring
HDL-C may not be sufficient for ideal risk assessment.
Therefore, alternative or complementary risk markerassessment, such as measuring HDL components (apo
A1) and composition, for determining CHD risk may
need to be utilized. The purpose of this study was to
evaluate a novel lipid ratio: apo A1 remnant ratio (apo
A1/[VLDL3-C+IDL-C]), which takes into account the
importance of both apo A1 and remnant lipoproteins,
with their association to death and myocardial infarc-
tion (MI) among peri and post-menopausal women.
Furthermore, the utility of this new ratio was compared
to traditional lipid parameters, apo A1, apo B, and the
ratios total cholesterol to HDL-C (TChol/HDL-C), TG/
HDL-C, apo B/A1, and HDL-C/(VLDL3-C+IDL-C).
Results
Patient characteristics
A total of 711 women met inclusion criteria and were
evaluated for this study. Average lipid and lipoprotein
levels among the entire cohort were (mg/dL): HDL-C:
48.3±15.6, LDL-C: 106.7±37.3, non-HDL-C: 136.5±41.3,
apo B: 76.7±18.3, apo B/A1 ratio: 0.66±0.18, apo A1:
119.7±20.3, apo A1/(VLDL3-C+IDL-C): 6.6±3.6, TChol/
HDL-C ratio: 4.3±2.8, VLDL3-C+IDL-C: 22.1±9.1, HDL-
C/(VLDL3-C+IDL-C): 2.1±1.4, and LDL-C/HDL-C:
2.5±1.8. Triglycerides and the TG/HDL-C ratio were
non-normally distributed and therefore, the median
levels are reported: 133.0 mg/dL and 2.9, respectively.
Patient characteristics for the cohort are shown in
Table 1. A total of 41.3% of patients were discharged on
a lipid lowering medication (37.1% were statins), 42.1%
on aspirin, 27% on an ACEI, 17.4% on an ARB, and
33.9% on a beta-blocker.
Long-term outcomes
Lipoprotein ratios and individual particles were the best
predictors of short-term (1 year) and intermediate-term
(3 year) death/MI risk (Table 2). After adjustment, there
was a significant association between tertiles of the apo
Table 2 Death/MI event rates at 1 and 3 years among lipid and lipoprotein tertiles
Outcome Tertile 1 Tertile 2 Tertile 3 p-trend
Apo A1/(VLDL3-C+IDL-C)
1 year Death/MI 9.7% (23) 7.6% (18) 6.3% (15) 0.17
3 year Death/MI 17.3% (41) 15.6% (37) 9.3% (22) 0.01
Apo A1
1 year Death/MI 11.4% (27) 5.5% (13) 6.8% (16) 0.06
3 year Death/MI 21.1% (50) 9.3% (22) 11.8% (28) 0.004
Apo B
1 year Death/MI 6.3% (15) 10.1% (24) 7.2% (17) 0.27
3 year Death/MI 13.9% (33) 16.0% (38) 12.2% (29) 0.49
Apo B/A1
1 year Death/MI 7.2% (17) 5.1% (12) 11.4% (27) 0.03
3 year Death/MI 12.2% (29) 11.4% (27) 18.6% (44) 0.05
HDL-C
1 year Death/MI 8.4% (20) 6.6% (15) 8.5% (21) 0.98
3 year Death/MI 18.6% (44) 10.2% (23) 13.3% (33) 0.10
Triglycerides
1 year Death/MI 7.7% (18) 9.2% (22) 6.8% (16) 0.72
3 year Death/MI 12.3% (29) 15.4% (37) 14.4% (34) 0.52
LDL-C
1 year Death/MI 8.3% (20) 8.2% (19) 7.1% (17) 0.63
3 year Death/MI 16.3% (39) 12.9% (30) 13.0% (31) 0.31
non-HDL-C
1 year Death/MI 6.8% (16) 10.2% (24) 6.7% (16) 0.96
3 year Death/MI 14.0% (33) 16.6% (39) 11.7% (28) 0.46
Triglycerides/HDL-C Ratio
1 year Death/MI 7.9% (23) 9.1% (21) 6.4% (12) 0.64
3 year Death/MI 11.6% (34) 17.2% (40) 13.9% (26) 0.37
VLDL3-C+IDL-C
1 year Death/MI 6.8% (17) 7.4% (16) 9.3% (23) 0.29
3 year Death/MI 11.6% (29) 15.8% (34) 15.0% (37) 0.27
Total Cholesterol/HDL-C Ratio
1 year Death/MI 8.9% (21) 7.6% (18) 7.2% (17) 0.78
3 year Death/MI 13.5% (32) 12.6% (30) 16.1% (38) 0.52
HDL-C/(VLDL3-C+IDL-C)
1 year Death/MI 10.6% (25) 6.3% (15) 6.7% (16) 0.12
3 year Death/MI 19.1% (45) 13.0% (31) 10.1% (24) 0.005
LDL-C/HDL-C
1 year Death/MI 9.7% (23) 5.5% (13) 8.4% (20) 0.61
3 year Death/MI 14.3% (34) 11.4% (27) 16.5% (39) 0.51
Apo: apolipoprotein; HDL-C: high density lipoprotein cholesterol; IDL-C: intermediate density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol;
VLDL-C: very low density lipoprotein3 cholesterol.
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Table 3 Multivariable association of tertiles of lipoprotein
and lipid parameters for 1 and 3 year Death/MI
Outcome 1 year death/MI 3 year death/MI
Apo A1-C/(VLDL3-C+IDL-C)
Tertile 1 vs. Tertile 3 HR=2.14, p=0.03 HR=2.33, p=0.003
Tertile 2 vs. Tertile 3 HR=1.52, p=0.27 HR=1.95, p=0.02
Apo A1
Tertile 1 vs. Tertile 3 HR=1.81, p=0.07 HR=1.80, p=0.02
Tertile 2 vs. Tertile 3 HR=0.77, p=0.49 HR=0.72, p=0.27
Apo B
Tertile 2 vs. Tertile 1 HR=1.70, p=0.11 HR=1.18, p=0.49
Tertile 3 vs. Tertile 1 HR=1.34 p=0.42 HR=0.96, p=0.89
Apo B/A1 Ratio
Tertile 2 vs. Tertile 1 HR=0.76, p=0.48 HR=0.94, p=0.82
Tertile 3 vs. Tertile 1 HR=1.97, p=0.03 HR=1.83, p=0.01
HDL-C
Tertile 1 vs. Tertile 3 HR=0.96, p=0.89 HR=1.19, p=0.48
Tertile 2 vs. Tertile 3 HR=0.72, p=0.36 HR=0.62, p=0.10
Triglycerides
Tertile 2 vs. Tertile 1 HR=1.56, p=0.20 HR=1.48, p=0.14
Tertile 3 vs. Tertile 1 HR=1.19, p=0.65 HR=1.26, p=0.40
LDL-C
Tertile 2 vs. Tertile 1 HR=0.88, p=0.73 HR=0.74, p=0.26
Tertile 3 vs. Tertile 1 HR=1.35, p=0.38 HR=1.09, p=0.74
Non-HDL-C
Tertile 2 vs. Tertile 1 HR=1.19, p=0.62 HR=1.11, p=0.69
Tertile 3 vs. Tertile 1 HR=1.30, p=0.47 HR=1.002, p=0.99
Triglycerides/HDL-C Ratio
Tertile 2 vs. Tertile 1 HR=1.10, p=0.76 HR=1.53, p=0.08
Tertile 3 vs. Tertile 1 HR=0.90, p=0.77 HR=1.20, p=0.50
VLDL3-C+IDL-C
Tertile 2 vs. Tertile 1 HR=1.31, p=0.45 HR=1.46, p=0.14
Tertile 3 vs. Tertile 1 HR=1.90, p=0.05 HR=1.55, p=0.09
Total Cholesterol/HDL-C Ratio
Tertile 2 vs. Tertile 1 HR=0.89, p=0.72 HR=0.96, p=0.87
Tertile 3 vs. Tertile 1 HR=0.91, p=0.77 HR=1.27, p=0.33
HDL-C/(VLDL3-C+IDL-C)
Tertile 1 vs. Tertile 3 HR=1.70, p=0.10 HR=2.07, p=0.004
Tertile 2 vs. Tertile 3 HR=0.97, p=0.92 HR=1.35, p=0.27
LDL-C/HDL-C
Tertile 2 vs. Tertile 1 HR=0.60, p=0.15 HR=0.89, p=0.64
Tertile 3 vs. Tertile 1 HR=0.96, p=0.90 HR=1.15, p=0.57
Apo: apolipoprotein; HDL-C: high density lipoprotein cholesterol; IDL-C:
intermediate density lipoprotein cholesterol; LDL-C: low density lipoprotein
cholesterol; VLDL-C: very low density lipoprotein3 cholesterol.
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(Table 3). Tertile 1 for both apo A1 and HDL-C/(VLDL3-
C+IDL-C) were significantly associated with increased risk
at 3 years when compared to tertile 3. Though significance
was not achieved at 1 year for death/MI for both apo A1
and HDL-C/(VLDL3-C+IDL-C), tertile 1 vs. tertile 3 had
clinically meaningful hazard ratios (1.81 and 1.70, respect-
ively). The remnants, VLDL3-C+IDL-C, were associated
with 1 year death/MI for tertile 3 vs. tertile 1. Tertile 3 vs.
tertile 1 for the apo B/A1 ratio was a significant predictor
of death/MI at both 1 and 3 years. Longitudinal associa-
tions of tertiles of the apo A1 remnant ratio are displayed
in Figure 1 for 1 year (a) and 3 year (b) death/MI. Though,
the log rank p-value did not achieve significance at 1 year
(most likely attributable to a lower event rate), there is a
clear separation between the curves that show a distinct
risk between the tertiles.
The Apo A1 remnant ratio: apo A1/ (VLDL3-C+IDL-C)
We evaluated whether we could better stratify risk predic-
tion beyond tertiles. Therefore, using recursive partitioning,
we determined that the cutoffs of ≤3.5 (category 1,
n=98), >3.5-6.0 (category 2, n=310), and >6.0 (category 3,
n=303) were the ideal categorizations for stratifying death/
MI risk. The sensitivity and specificity at 3.5 (cutoff be-
tween categories 1 and 2) were 0.786 and 0.870 at 1 year
and 0.80 and 0.872 at 3 year, respectively. For the cutoff of
6.0 (between categories 2 and 3), the sensitivity and specifi-
city were 0.286 and 0.438 at 1 year and 0.270 and 0.452 at 3
years, respectively. Therefore, the categories were good dis-
criminators between those at low and moderate-to-high
risk. Baseline characteristics across categories of the apo A1
remnant ratio are shown in Table 4. Those in category 1
were more likely to have hypertension, hyperlipidemia, and
diabetes; whereas, those in categories 2 and 3 had greater
use of lipid lowering drugs, including statins. A better lipid
profile was seen progressively across apo A1 remnant ratio
categories.
Figure 2 displays the frequency of events among the cat-
egories of the apo A1 remnant ratio, with a significant trend
of increasing risk with decreasing levels. After adjustment,
all category comparisons at both timepoints significantly
predicted death/MI risk (Figure 3). When comparing tertile
1 to tertile 3 and tertile 2 to tertile 3, there was an approxi-
mate 2.5-fold and a 2-fold increase in risk for death/MI at
both timepoints, respectively. These associations remained
with little attenuation after adjustment by LDL-C, HDL-C,
and non-HDL-C. Log-transformed triglycerides (r=−702),
apo A1 (r=0.510), apo B/A1 (r=−0.58), and VLDL3-C+IDL-
C (r=−0.76) were significantly correlated with the apo A1
remnant ratio and therefore could not be evaluated in the
multivariable model. Longitudinal associations for 1 year
and 3 year death/MI are shown in Figure 4. As with the
tertiles, the log rank p-value for the apo A1 remnant ratio
ab
Figure 1 Longitudinal associations of tertiles of the apolipoprotein A1 remnant ratio (apo A1/ [VLDL3-C+IDL-C]) at a) 1 year death/MI
(log rank p-value=0.40) and b) 3 year death/MI (log rank p-value=0.04).
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the curves do show a distinct difference in risk between the
categories. The predictive ability of the apo A1 remnant
ratio was similar among women when stratified by age
(50–64 vs. ≥65 years) and CAD status.
Discussion
This study presents for the first time in women greater
than 50 years of age that the novel apo A1 remnant ratio
(apo A1/[VLDL3-C+IDL-C]) is a strong predictor ofdeath/MI at 1 and 3 years. This is seen among both
tertiles, as well as from categories derived from recursive
partitioning. Furthermore, this ratio had greater predict-
ive ability than traditional lipid parameters, apo A1, apo
B, and ratios such as TChol/HDL-C, TG/HDL-C, apo
B/A1, and HDL-C/(VLDL3-C+IDL-C). The power of this
ratio is related to both the numerator (apo A1) and the
remnant denominator (VLDL3-C+IDL-C).
There are potentially important clinical ramifications
related to this new ratio. As women age, LDL-C and
Table 4 Baseline characteristics among categories of the apo A1 remnant ratio (apo A1/ [VLDL3-C+IDL-C])
Characteristic Category 1 (n=98) Category 2 (n=310) Category 3 (n=303) p-value
Age (year) 68.5±9.2 67.3±9.0 68.0±9.9 0.44
Hypertension 72.4% 70.6% 55.8% <0.0001
Hyperlipidemia 60.2% 51.3% 45.2% 0.03
Diabetes 33.7% 20.6% 18.2% 0.005
Metabolic Syndrome 53.1% 32.6% 22.8% <0.0001
Family History of CAD 45.9% 42.9% 40.6% 0.63
Smoking 10.2% 14.5% 11.6% 0.40
Prior CAD 44.0% 36.1% 38.2% 0.43
Prior MI 5.1% 6.5% 5.3% 0.79
Presentation 0.53
Stable Angina 59.2% 65.2% 60.1%
Unstable Angina 30.6% 23.5% 29.0%
MI 10.2% 11.3% 10.9%
CAD 44.9% 41.9% 44.2% 0.80
Any Lipid Lower 27.4% 45.2% 42.0% 0.03
Statin 23.3% 42.1% 36.6% 0.02
Aspirin 42.5% 40.7% 43.4% 0.85
ACE Inhibitor 30.1% 31.2% 21.4% 0.06
ARB 16.4% 19.7% 15.1% 0.44
Beta-blocker 39.7% 32.3% 33.5% 0.50
LDL-C (mg/dL) 119.9±48.9 106.4±35.1 102.7±34.2 <0.0001
HDL-C (mg/dL) 41.7±14.9 46.1±13.7 52.7±16.6 <0.0001
Triglycerides (mg/dL)* 176.0 145.0 116.0 <0.0001
Apo A1 (mg/dL) 106.2±14.6 115.0±17.0 128.9±20.9 <0.0001
Apo B (mg/dL) 93.4±21.2 78.5±15.6 69.4±15.6 <0.0001
Apo B/Apo A1 Ratio 0.89±0.19 0.69±0.13 0.55±0.14 <0.0001
non-HDL-C (mg/dL) 158.0±55.1 137.7±37.3 128.2±37.2 <0.0001
Triglycerides/HDL-C Ratio* 4.7 3.2 2.3 <0.0001
VLDL3-C+IDL-C (mg/dL) 37.1±7.6 24.6±5.1 14.6±3.8 <0.0001
Total Cholesterol/HDL-C Ratio 5.1±1.6 4.4±2.9 3.9±2.9 <0.0001
*Median reported due to non-normal distribution.
Apo: apolipoprotein; ARB: angiotensin receptor blocker; CAD: coronary artery disease; HDL-C: high density lipoprotein cholesterol; IDL-C: intermediate density
lipoprotein cholesterol LDL-C: low density lipoprotein cholesterol; mg/dL: milligrams/deciliter; MI: myocardial infarction; VLDL-C: very low density
lipoprotein3 cholesterol.
Categories were determined by recursive partitioning and were stratified into the following: category 1: ≤3.5 mg/dL; category 2: 3.5-6.0 mg/dL; category
3: >6.0 mg/dL.
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position [3]. It has been shown that the specific compos-
ition of HDL alters its capacity to participate in reverse
cholesterol transport and modulate inflammation. There-
fore, measurements of traditional lipid parameters may
not be sufficient in risk prediction. This study reinforces
the growing body of evidence that among post- meno-
pausal women, LDL-C, which is the current target of lipid
therapy by the National Cholesterol Education Panel
Adult Treatment Panel (NCEP ATP) III report [23], is not
the most predictive lipid parameter for CHD risk [5,24].In addition, remnant lipoproteins are known to be ele-
vated in postmenopausal women [8] and emphasis on
remnant lipoproteins has been highlighted in the NCEP
ATP III guidelines, which recommends the calculation of
non-HDL-C as its measure [24]. Although non-HDL-C
provides a measure of remnant lipoproteins, it also is a
measure of triglyceride-rich particles, which are less
atherogenic. Another advantage of the apo A1 remnant
ratio is that fasting is not required for sub-fraction mea-
surements and therefore it could be precisely calculated.



























Figure 2 Death/MI event rates at 1 and 3 years among
categories of the apolipoprotein (apo) A1 remnant ratio (apo
A1/ [VLDL3-C+IDL-C]). * Category 1 (≤3.5), Category 2 (>3.5-6.0),
and Category 3 (>6.0).
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apo A1 and the remnant lipoproteins over traditional lipid
parameters.
Apo A1, which is the major protein component of
HDL, is largely responsible for reverse cholesterol trans-
port through the macrophage ATP-binding cassette
transporter ABCA1. Oxidative mechanisms can damage
apo A1, which decreases its ability to effectively promote
cholesterol efflux. Such modifications can convert HDL
from an anti-inflammatory to a pro-inflammatory par-
ticle. Measuring HDL-C is indicative of the size of the
HDL pool, but not its composition. Therefore, an advan-
tage of utilizing apo A1 over HDL-C is that it reflects
the functioning-state of the molecule. Though epidemio-
logical studies have consistently shown HDL-C to be in-
versely correlated with atherosclerotic events [25,26],Figure 3 Adjusted hazard ratios (HR) of categories of the apo
A1 remnant ratio (apo A1/ [VLDL3-C+IDL-C]) at 1 year and 3
year death/MI.particularly among women [4], many events continue to
occur despite reaching target levels [6]. Thus, emphasiz-
ing the need to determine additional measurements that
can identify risk among “low-risk” populations. Further,
it appears that HDL-C has a U-shaped distribution with
a threshold for the upper limit of normal not being con-
sistently defined for identifying risk, whereas apo A1 has
a constant inverse relationship with CHD events [26].
Also, dysfunctional HDL is not always reflected in the
HDL-C pool [27]. Unlike apo A1, very high values of
HDL-C and HDL particle size have been shown to be
associated with increased major adverse cardiovascular
event risk [28].
We found low levels of apo A1 to be associated with
an 80% increase in 1 and 3 year death/MI risk, whereas
levels of HDL-C were found to not be predictive. The
apo A1 remnant ratio utilizes the predictive value of apo
A1, which was found to be highly predictive of death/MI
by tertiles and by categories. We evaluated whether
HDL-C would elicit similar results as apo A1 when
divided by the remnant lipoproteins since a previous
investigation found the inverse of this ratio, (VLDL3–
C+IDL-C)/HDL-C, to be predictive of CHD [29]. We
found the HDL-C/(VLDL3-C+ IDL-C) ratio, though pre-
dictive, to not achieve the same degree of predictive
significance as the apo A1 remnant ratio. These results
reinforce the importance of measuring apo A1, poten-
tially above that of HDL-C, for determining death/MI
risk among women >50 years.
Remnant lipoproteins are generated by lipolysis of
triglyceride-rich lipoproteins and have been shown to play
a greater role in CHD development than their precursors
[11]. The Framingham Heart Study found remnant lipo-
proteins to be significantly higher in women with CHD
when compared to women without CHD [8]. Among
postmenopausal women, Lamon-Fava et al. reported that
atherosclerosis severity is linked to a dysregulation of tri-
glyceride/HDL metabolism [19]. They hypothesized that
increases in remnant lipoproteins may be associated with
increased lipid deposition in the arterial wall, plaque for-
mation, and the generation of HDL-C subpopulations that
are less efficient in the reverse cholesterol removal from
the arterial wall [19]. Remnant lipoproteins, independent
of cardiovascular risk factors, have also been shown to be
associated with peripheral vascular endothelial dysfunction
as measured by Doppler flow analysis [30], with this be-
ing more pronounced in the postprandial state [31].
Furthermore, remnant lipoproteins directly promote the
initial stages of atherosclerosis through regulating the
expression of ICAM-1 and VCAM-1, which are re-
quired for attachment of monocytes to the endothelial
wall [32]. In addition, they have been shown to promote
a pro-coagulant state and induce tissue factor in cul-
tured endothelial cells, with large and small VLDLs
ab
Figure 4 Longitudinal associations of categories of the apo A1 remnant ratio (apo A1/ [VLDL3-C+IDL-C]) at a) 1 year death/MI (log rank
p-value=0.40) and b) 3 year death/MI (log rank p-value=0.04). * Category 1 (≤3.5), Category 2 (>3.5-6.0), and Category 3 (>6.0).
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VII activation [32,33]. Finally, VLDL particles generate
thrombin at rates near that of activated platelets [34].
These pro-inflammatory, pro-atherogenic, and pro-
thrombotic effects of remnant lipoproteins, which are
independent from traditional risk factors including
LDL-C, further explain the increased event rate seen in
patients with CHD and increased remnant lipoprotein
levels [35]. Finally, it is possible that remnant lipopro-
teins may be the driving factor of the increased CHDrisk seen in middle aged and older woman with elevated
triglycerides [36-41]. Within our study, remnant eleva-
tions were found to be associated with 1 year death/MI
(HR=1.90, p=0.05), with a trend toward significance for
3 year death/MI risk (HR=1.55, p=0.09). Triglycerides
were not associated with death/MI risk.
Many lipid and sub-lipid ratios have been reported to
predict CHD risk. In the Women’s Ischemia Syndrome
Evaluation (WISE) study, the TG/HDL-C ratio was found
to predict cardiovascular events and mortality among
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non-HDL-C, the TChol/HDL-C ratio, and total cholesterol
were not [13]. However, the TG/HDL-C was no longer
predictive of cardiovascular events when adjusted by coron-
ary artery disease severity. Within our study the apo A1
remnant ratio maintained its significance after adjustment
by CHD severity. The TG/HDL-C ratio has also been
shown to be predictive of cardiovascular events among
other populations [14,15]. However, we found the TG/
HDL-C ratio to be not predictive of 1 or 3 year death/MI
among women >50 years.
The apo B/A1 ratio was shown in INTERHEART, a
large, international case–control study, to be one of the
most predictive parameters for identifying CHD risk [9].
It was also found to show a graded relationship with MI
risk, with no evidence of a threshold. Of all of the risk
factors evaluated, the apo B/A1 ratio contributed the
greatest to the population attributable risk, even being
superior to smoking. When stratified by sex and age, simi-
lar associations persisted across all sub-groups. AMORIS
showed that apo B, apo A1, and the apo B/A1 ratio are
important risk factors for fatal MI, even after adjustment
by age, total cholesterol, and triglycerides, with the apo B/
A1 ratio being the greatest predictor of risk [7]. These re-
sults were consistent among both men and women, young
(<70 years) and old (≥70 years). The apo B/A1 ratio was
predictive of 1 year and 3 year death/MI when the highest
tertile was compared to the lowest tertile within our study,
though its predictive power was not as strong as the apo
A1 remnant ratio.
In a recent meta-analysis that evaluated 233,455 sub-
jects with 22,950 events, apo B was found to be superior
to non-HDL-C, which in turn was superior to LDL-C in
predicting cardiovascular risk (RR=1.43, 1.34, 1.25, re-
spectively) [42]. Furthermore, this study found that using
an apo B strategy to treat those individuals at >70th per-
centile in the US adult population, 500,000 more events
would have been prevented than if a non-HDL-C stategy
had not been used. It has also been reported that apo B
is a more accurate marker of cardiovascular risk than
LDL-C, and in its absence, non-HDL-C should be used
since it indirectly estimates apo B [43]. Our study showed
that the apo A1 remnant ratio was more predictive than
apo B or non-HDL-C. One explanation for this is that
remnant lipoproteins are more atherogenic than other lar-
ger apo B containing triglyceride rich lipoproteins. Rem-
nants are smaller particles and can diffuse into the arterial
wall [44] and are more likely to be bound by heparin sul-
fate proteoglycans within the arterial media [45]; there-
fore, able to promote more events.
Results of this study seem to suggest that lipids, or
some of their components, might not be the best indica-
tor of increased risk and those with a greater concentra-
tion of denser, more atherogenic particles are at higherrisk than in those with abnormal lipid concentrations.
Therefore, the apo A1 remnant ratio may be a parameter
that may better stratify risk of women >50 years so that
those found in the higher risk categories can be more
aggressively treated. Interventions may include earlier
introduction or more aggressive lipid-lowering therapy.
In this study, there was a significant difference between
the use of lipid lowering medications among the categor-
ies at baseline, though lipid lowering use was adjusted
for in the multivariable model, use of these medications
could have affected which stratification, and thus risk of
the patient. Future studies should evaluate longitudinal
use of lipid lowering therapy on apo A1 remnant ratio
levels. The apo A1 remnant ratio is indicative of the
number of anti-atherogenic particles over the number of
atherogenic particles. Thus, particle numbers and their
ratios might be more important factors than the amount
of lipids carried per particle.
Study limitations
This study shares the limitations of all nonrandomized,
observational studies, including the possibility of selec-
tion bias and unadjusted confounding. The population
studied was high-risk (i.e., undergoing angiography), pre-
dominantly white, and women >50 years of age; thus
these results may not apply to lower-risk populations,
men, women ≤50 years, and other ethnic groups. The
menopausal status in all women was not known; how-
ever approximately 80% of women over the age of 50 are
either peri- or post-menopausal [46]. Therefore, the lipid
changes associated with menopause might not be seen
among all of the women and be non-randomly distrib-
uted across tertiles and categories. Further, we did not
know the status of hormone replacement therapy, which
positively affects lipid and lipoprotein profiles [47]. It is
possible that there is a significant difference in the use
of these medications across the lipid and lipoprotein
tertiles and categories, which could have possible effects
on the associations. We did not know the insulin resist-
ance status of our patients, as insulin levels were not
available to provide a calculation of HOMA-IR. How-
ever, 31.2% of our patients had metabolic syndrome and
21.4% had diabetes mellitus, with the apo A1 remnant
ratio remaining statistically significant despite adjustment.
The results of this study were confined to “hard” cardio-
vascular end points (death/MI); thus, we cannot give con-
clusions regarding “softer” cardiovascular endpoints such
as angina, hospitalization, and revascularization.
Conclusions
The new parameter, the apo A1 remnant ratio, was
found to be a significant predictor of short-term and
intermediate-term death/MI risk among women >50
years of age and was more strongly associated with
Table 5 Lipid and lipoprotein tertile stratifications
Tertile 1 Tertile 2 Tertile 3
Apo A1/(VLDL3-C+IDL-C) <4.7 4.7-6.8 >6.8
Apo A1 <109.7 109.7-127.2 >127.2
Apo B <67.3 67.3-81.9 >81.9
Apo B/A1 Ratio <0.57 0.57-0.71 >0.71
HDL-C <40 40-52 >52
Triglycerides <113 113-160 >160
LDL-C <88 88-117 >117
Non-HDL-C <119 119-146 >146
Triglycerides/HDL-C Ratio <2.3 2.3-3.7 >3.7
VLDL3-C+IDL-C <17 17-24 >24
Total Cholesterol/HDL-C Ratio <3.4 3.4-4.4 >4.4
HDL-C/(VLDL3-C+IDL-C) <1.4 1.4-2.1 >2.1
LDL-C/HDL-C <1.8 1.8-2.7 >2.7
Apo: apolipoprotein; HDL-C: high density lipoprotein cholesterol; IDL-C:
intermediate density lipoprotein cholesterol; LDL-C: low density lipoprotein
cholesterol; VLDL-C: very low density lipoprotein3 cholesterol.
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apo B, and well-recognized lipid ratios. Further, this
new ratio brings attention to the role of remnant lipo-
proteins in women greater than 50 years of age and rep-
resents a potential new measurement of risk. The apo
A1 remnant ratio should be evaluated as a potential
new treatment target and should be tested in a larger
cohort and among other populations.
Methods
Study patients
Study patients were drawn from the Intermountain
Heart Collaborative Study (IHCS) registry from March,
1999 to January, 2007 [48,49]. The IHCS is a cardiac
catheterization registry that includes consenting patients
undergoing catheterization at a major Intermountain
Healthcare hospital (LDS Hospital: Salt Lake City, UT;
Intermountain Medical Center: Murray, UT; and McKay
Dee Hospital: Ogden, UT). At the time of angiography,
patients that provided informed consent had a blood sam-
ple taken and stored cryogenically for future testing. Pa-
tients (N=711) were included in this study if they were
female, >50 years of age, gave written informed consent,
and had both lipid panel results available from hos-
pitalization and lipoprotein subfraction measurements.
The Intermountain Healthcare Urban Central Institu-
tional Review Board approved this study.
Lipid and lipoprotein particle quantification and
stratification
Lipid levels were obtained during angiography hos-
pitalization at the discretion of the attending cardiolo-
gist. Total cholesterol and triglycerides were quantified
using dry-slide measurement on the VITROS 950
Analyzer (Ortho Clinical Diagnostics; Rochester, NY).
HDL-C was measured with the same instrument follow-
ing treatment with VITROS HDL-Cholesterol Magnetic
Reagent. LDL-C and VLDL-C were calculated from the
total cholesterol and triglyceride measurements.
At the time of angiography, blood samples were col-
lected in EDTA and refrigerated at 4°C. Within 24 hours,
samples were centrifuged and plasma and DNA were sep-
arated and stored cryogenically. Cholesterol concentra-
tions of lipoprotein classes and their subclasses were
measured on samples obtained at angiography using single
vertical spin density gradient ultra-centrifugation based on
the Vertical Auto Profile (Atherotech, Birmingham, AL)
[50]. Apo A1 was estimated by the VAP method using the
procedure described previously [51].
Lipids and lipoproteins were evaluated as tertiles.
Tertile stratifications for the different parameters are
displayed in Table 5. For the apo A1 remnant ratio, apo
A1, HDL-C, and HDL-C/(VLDL3-C+IDL-C) higher
levels are desirable. However, lower levels are desiredfor triglycerides, LDL-C, non-HDL-C, apo B, apo B/A1
ratio, TG/HDL-C ratio, VLDL3-C+IDL-C, TChol/HDL-
C ratio, and the LDL-C/HDL-C ratio.
Other risk factor, demographic, and clinical assessments
In addition to age and gender, patient information col-
lected included diabetes status (diabetes mellitus: fasting
blood glucose > 125 mg/dL, clinical diagnosis of diabetes
mellitus, or anti-diabetic medication use; insulin resist-
ance: fasting glucose between 110–125 mg/dL; and nor-
mal: fasting glucose <110 mg/dL), hypertension (systolic
blood pressure ≥ 140 mmHg, diastolic ≥ 90 mmHg, or
anti-hypertensive use), renal failure (clinical diagnosis or
GFR <15 ml/min), hyperlipidemia (total cholesterol ≥ 200
mg/dL, LDL ≥ 130 mg/dL, or cholesterol-lowering medica-
tion use), and congestive heart failure (clinical diagnosis or
physician-reported). The metabolic syndrome was defined
using ATP III criteria [52], with BMI >27 kg/m2 used as a
surrogate for waist circumference. Family history was
patient-reported if a first-order relative had suffered cardio-
vascular death, MI, or coronary revascularization before
age 65 years. Smoking included active smokers or those
with a >10 pack-year history. Clinical presentation included
stable angina (stable exertional symptoms only), unstable
angina (progressive symptoms or symptoms at rest), or
acute MI (creatine kinase-MB >6 mg/dL and creatine
kinase-MB index >3% or a troponin I level >0.4 ng/mL).
Treatment type was defined as treatment with medication
only, percutaneous coronary intervention, or coronary ar-
tery by-pass surgery. Admission and discharge medications
(i.e., statin, other lipid lowering medications, ace-inhibitors
[ACEI], aspirin, angiotensin receptor blocker [ARB], beta-
blocker, clopidogrel, diuretic) were also available.
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more ≥ 70% obstructive lesions by coronary artery angi-
ography. Assessment of CAD was made by review of an-
giograms by the patient’s cardiologist, and results were
entered into the computer database in a format modified
after the coronary artery surgery study protocol [49]. On
the basis of this angiographic evaluation, the patients
were determined to have single-, double-, or triple-vessel
disease as defined by the presence of a 70% stenosis in
each major vessel counted, with the left main counting
as two vessels. Assessment of CAD was performed
blinded to results of blood testing.
Patient follow-Up and event assessment
Average length of follow-up was 3.9±2.1 years. Events
included the composite outcome of death and non-fatal
MI at 1 and 3 years. MI was defined as a hospitalization
where a patient had a troponin I level ≥0.4 ng/mL or a
discharge diagnosis of an MI (ICD-9 code 410). Deaths
were determined by telephone survey, hospital records,
and Utah State Health Department records (death certif-
icates) and were verified through Social Security death
records. Patients not listed as deceased in any registry
were considered to be alive.
Statistical analysis
The chi-square test, Student’s t test, and the analysis
variance (ANOVA) were used to examine lipid and lipo-
protein tertiles to baseline characteristics. To confirm
the associations of the composite outcome of death/MI
determined by univariable analysis, multivariable Cox
hazard regression (SPSS, version 15.0; Chicago, IL) was
performed to determine hazard ratios (HRs). Kaplan-
Meier survival estimates and the log rank test were used
to determine initial associations with 1 and 3 year death/
MI. Available baseline risk factors used in the modeling
included age, gender, hypertension, hyperlipidemia, dia-
betes status, smoking, family history of CAD, renal fail-
ure, prior MI, prior cerebrovascular accident, congestive
heart failure, presentation (stable angina, unstable angina,
or acute MI), number of vessels with stenosis ≥70%, and
discharge medications. Final models entered significant
(p<0.05) and confounding (10% change in beta-coefficient)
covariables. The proportional hazards assumption was
met for all models. Two-tailed p-values are presented with
0.05 designated as nominally significant.
Abbreviations
Apo: Apolipoprotein; MI: Myocardial infarction; T: Tertile; CHD: Coronary heart
disease; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density
lipoprotein cholesterol; IDL-C: Intermediate-density lipoprotein cholesterol;
VLDL-C: Very low-density lipoprotein cholesterol; TG: Triglyceride;
CAD: Coronary artery disease; TChol: Total cholesterol; IHCS: Intermountain
Heart Collaborative Study; ACEI: Ace-inhibitors; ARB: Angiotensin receptor
blocker; ANOVA: Analysis variance; HR: Hazard ratio; NCEP ATP: National
Cholesterol Education Panel Adult Treatment Panel.Competing interests
HTM: none. JRN: consultant for Atherotech. KRK: employee of Atherotech.
JLA: none. BDH: none. TLB: none. JBM: none.
Authors’ contributions
HTM participated in the study design, performed the statistical analysis, and
the writing of the manuscript. JRN participated in the study design and
writing of the manuscript. KRK participated in the study design and critical
revision of the manuscript. JLA participated in the critical revision of the
manuscript. BDH participated in the critical revision of the manuscript. TLB
participated in data acquisition and the critical revision of the manuscript.
JBM participated in the study design and critical revision of the manuscript.
All authors read and approved the final manuscript.
Financial support
In-kind support from Atherotech, Birmingham, AL.
Author details
1Intermountain Medical Center, Cardiovascular Department, 5121 S.
Cottonwood Street, Murray, UT 84157, USA. 2UCSF, Fresno, CA, USA.
3Atherotech, Birmingham, AL, USA. 4University of Utah, Salt Lake City,
UT, USA.
Received: 1 March 2013 Accepted: 18 April 2013
Published: 26 April 2013
References
1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM,
Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie
C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner
SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A,
Matchar DB, McDermott MM, Meigs JB, Moy CS, on behalf of the American
Heart Association Statistics Committee and Stroke Statistics Subcommittee,
et al: Heart disease and stroke statistics—2011 update: a report from the
American Heart Association. Circulation 2011, 123:e18–e209 [published
correction appears in Circulation. 2011;123:e240].
2. Manson JE: Prevention of myocardial infarction. New York: Oxford University
Press; 1996.
3. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan
WR: Cholesterol and heart disease in older persons and women. Review
of an NHLBI workshop. Ann Epidemiol 1992, 2:161–176.
4. Eaker ED, Chesebro JH, Sacks FM, Wenger NK, Whisnant JP, Winston M:
Cardiovascular disease in women. Circulation 1993, 88:1999–2009.
5. Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, Stampfer MJ,
Ma J: Multivariate assessment of lipid parameters as predictors of
coronary heart disease among postmenopausal women: potential
implications for clinical guidelines. Circulation 2004, 110:2824–2830.
6. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density
lipoprotein as a protective factor against coronary heart disease. The
Framingham Study. Am J Med 1977, 62:707–714.
7. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High
apolipoprotein B, low apolipoprotein A-I, and improvement in the
prediction of fatal myocardial infarction (AMORIS study): A prospective
study. Lancet 2001, 358:2026–2033.
8. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PWF, Ordovas JM,
Schaefer EJ: Remnant-like particle (RLP) cholesterol is an independent
cardiovascular disease risk factor in women: results from the
Framingham Heart Study. Atherosclerosis 2001, 154:229–236.
9. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, McQueen M,
Budaj A, Pais P, Varigos J, Lisheng L, on behalf of the INTERHEART Study
Investigators: Effect of potentially modifiable risk factors associated with
myocardial infarction in 52 countries (the INTERHEART study): case–
control study. Lancet 2004, 364:937–951.
10. Simons L, Dwyer T, Somons J, Bernstein L, Mock P, Poonia N,
Balasubramaniam S, Baron D, Branson J, Morgan P, Roy P: Chylomicrons
and chylomicron remnants in coronary artery disease: a case–control
study. Atherosclerosis 1987, 65:181–189.
11. Takeichi S, Yukawa N, Nakajima Y, Osawa M, Saito T, Seto Y, Nakano T,
Saniabadi AR, Adachi M, Wang T, Nakajima K: Association of plasma
triglyceride-rich lipoprotein remnants with coronary atherosclerosis in
cases of sudden cardiac death. Atherosclerosis 1999, 142:309–315.
May et al. Lipids in Health and Disease 2013, 12:55 Page 12 of 13
http://www.lipidworld.com/content/12/1/5512. Dobiasova M, Frohlich J: The plasma parameter log (TG/HDL-C) as an
atherogenic index: correlation with lipoprotein particle size and
esterification rate in apo B-lipoprotein-depleted plasma (FERHDL).
Clin Biochem 2001, 34:583–588.
13. Bitner V, Johnson D, Zineh I, Rogers WJ, Vido D, Marroquin OC, Bairey-Merz
CN, Sopko G: The triglyceride/high-density lipoprotein cholesterol ratio
predicts all-cause mortality in women with suspected myocardial
ischemia: A Report From the Women’s Ischemia Syndrome Evaluation
(WISE). Am Heart J 2009, 157:548–555.
14. Frohlich J, Dobiasova M: Fractional esterification rate of cholesterol and
ratio of triglycerides to HDL-cholesterol are powerful predictors of
positive findings on coronary angiography. Clin Chem 2003,
49:1873–1880.
15. Shishehbor MH, Hoogwerf BJ, Lauer MS: Association of triglyceride-to-HDL
cholesterol ratio with heart rate recovery. Diabetes Care 2004, 27:936–941.
16. Gofman J, Lindgren F, Elliott H, Mantz W, Hewitt J, Strisower B, Herring V,
Lyon TP: The role of lipids and lipoproteins in atherosclerosis. Science
1950, 111:166–171.
17. Satoh A, Adachi H, Tsuruta M, Hirai Y, Hiratsuka A, Enomot M, Furuki K, Hino
A, Takeuchi T, Imaizumi T: High plasma level of remnant-like particle
cholesterol in the metabolic syndrome. Diabetes Care 2005, 28:2514–2518.
18. Watanabe N, Taniguchi T, Taketoh H, Kitagawa Y, Namura H, Yoneda N,
Kurimoto Y, Yamada S, Ishikawa Y: Elevated remnant-like lipoprotein
particles in impaired glucose tolerance and type 2 diabetic patients.
Diabetes Care 1999, 22:152–156.
19. Lamon-Fava S, Herrington DM, Reboussin DM, Sherman M, Horvath KV,
Cupples A, White C, Demissie S, Schaefer EJ, Asztalos BF: Plasma levels of
HDL subpopulations and remnant lipoproteins predict the extent of
angiographically-defined coronary artery disease in postmenopausal
women. Arterioscler Thromb Vasc Biol 2008, 28:575–579.
20. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, Tsunoda R,
Sakamoto T, Nakano T, Nakajima K, Ogawa H, Sugiyama S, Yoshimura M, Yasue
H: Remnant lipoprotein levels in fasting serum predict coronary events in
patients with coronary artery disease. Circulation 1999, 99:2858–2860.
21. Phillips NR, Waters D, Havel RJ: Plasma lipoproteins and progression of
coronary artery disease evaluated by angiography and clinical events.
Circulation 1993, 88:2762–2770.
22. May HT, Kulkarni K, Horne BD, Anderson JL, Bair TL, Mower CP, Carlquist JF,
Muhlestein JB: Apolipoprotein A1 predicts future death and myocardial
infarction in patients undergoing coronary angiography even when they
have normal baseline HDL levels. J Am Coll Cardiol 2010,
55(10A):A55 (1128).
23. National Cholesterol Education Program Coordinating Committee: Third
report of the National Cholesterol Education Program (NCEP) expert
panel on detection, evaluation, and treatment of high blood cholesterol
in adults (adult treatment panel III) final report. Circulation 2002,
160:3143–3421.
24. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other
markers of inflammation in the prediction of cardiovascular disease in
women. N Engl J Med 2000, 342:836–843.
25. LaRosa JC: Lipids and cardiovascular disease: do the findings and therapy
apply equally to men and women? Wom Health Iss 1992, 2:111–113.
26. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J,
Qizilbash N, Peto R, Collins R, for the Prospective Studies Collaboration:
Blood cholesterol and vascular mortality by age, sex, and blood
pressure: a meta-analysis of individual data from 61 prospective studies
with 55,000 vascular deaths. Lancet 2007, 370:1829–1839.
27. HB G, Rao VS, Kakkar VV: Friend turns foe: transformation of ant-
inflammatory HDL to proinflammatory HDL during acute-phase
response. Cholesterol 2011, 274629. Epub 2010 Nov 25.
28. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES,
Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT,
Kastelein JJ: High-density lipoprotein cholesterol, high-density lipoprotein
particle size, and apolipoprotein A-1: significance for cardiovascular risk.
The IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008, 51:634–642.
29. Masuoka H, Ishikura K, Kamei S, Obe T, Seko T, Okuda K, Koyabu S, Tsuneoka
K, Tamai T, Sugawa M, Nakano T: Predictive value of remnant-like particles
cholesterol/high-density lipoprotein cholesterol ratio as a new indicator
of coronary artery disease. Am Heart J 1998, 136:226–230.
30. Funada J, Sekiya M, Otani T, Watanabe K, Akutsu H: Impact of high
remnant-like lipoproteins on the function of peripheral arterialendothelium in patients with hyperlipidemia and normolipidemia:
estimation using Doppler flow analysis. J Cardiol 2001, 37:267–276.
31. Maggi FM, Raselli S, Grigore L, Redaelli L, Fantappié S, Catapano A:
Lipoprotein remnants and endothelial dysfunction in the postprandial
phase. J Clin Endocrinol Metab 2004, 89:2946–2950.
32. Doi H, Kugiyama K, Oka H, Sugiyama S, Ogata N, Koide SI, Nakamura SI,
Yasue H: Remnant lipoproteins induce proatherothrombogenic
molecules in endothelial cells through a redox-sensitive mechanism.
Circulation 2000, 102:670–676.
33. Kjalke M, Silveira A, Hamsten A, Hedner U, Ezban M: Plasma lipoproteins
enhance tissue factor-independent factor VII activation. Arterioslcer
Thromb Vasc Biol 2000, 20:1835–1841.
34. Moyer MP, Tracy RP, Tracy PB, van’t Veer C, Sparks CE, Mann KG: Plasma
lipoproteins support prothrombinase and other procoagulant enzymatic
complexes. Arterioscler Thromb Vasc Biol 1998, 18:458–465.
35. Fukushima H, Sugiyama S, Honda O, Koide S, Nakamura S, Sakamoto T,
Yoshimura M, Ogawa H, Fujioka D, Kugiyama K: Prognostic value of
remnant-like lipoprotein particle levels in patients with coronary artery
disease and type II diabetes mellitus. J Am Coll Cardiol 2004,
43:2219–2224.
36. Johansson S, Wilhelmsen L, Lappas G, Rosengren A: High lipid levels and
coronary disease in women in Göteborg-outcome and secular trends: a
prospective 19 year follow-up in the BEDA study. Eur Heart J 2003,
24:704–716.
37. Stensvold I, Tverdal A, Urdal P, Graff-Iversen S: Non-fasting serum
triglyceride concentration and mortality from coronary heart disease
and any cause in middle aged Norwegian women. BMJ 1993,
307:1318–1322.
38. Mazza A, Tikhonoff V, Schiavon L, Casiglia E: Triglycerides + high-density
-lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly
women: the Cardiovascular Study in the Elderly. Intern Med J 2005,
35:604–610.
39. Simons LA, Friedlander Y, McCallum J, Simons J, Powell I, Heller R, Berry G:
The Dubbo study of the health of elderly: correlates of coronary heart
disease at study entry. J Am Geriatr Soc 1991, 39:584–590.
40. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S,
Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of
coronary heart disease: 10,158 incident cases among 262,525
participants in 29 Western prospective studies. Circulation 2007,
115:450–458.
41. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared
with nonfasting triglycerides and risk of cardiovascular events in
women. JAMA 2007, 298:309–316.
42. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf
J, Furberg CD: A meta-analysis of low-density lipoprotein cholesterol,
non-high-density lipoprotein cholesterol, and apolipoprotein B as
markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011,
4:337–345.
43. Sniderman A, McQueen M, Contois J, Williams K, Furberg CD: Why is non-
high-density lipoprotein cholesterol a better marker of the risk of
vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol
2010, 4:152–155.
44. Nordestgaard BG, Nielsen LB: Atherosclerosis and arterial influx of
lipoproteins. Curr Opin Lipidol 1994, 5:252–257.
45. Ji ZS, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW: Role of
heparin sulfate proteoglycans in the binding and uptake of
apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol
Chem 1993, 268:10160–10167.
46. Karnataka J: Nutritional status of menopausal women. Agric Sci 2008,
21:152–154.
47. Sanada M, Nakagawa H, Kodama I, Sakasita T, Ohama K: The effect of
hormone replacement therapy on metabolism of lipoprotein remnants
in postmenopausal women. Maturitas 2000, 34:75–82.
48. Taylor GS, Muhlestein JB, Wagner GS, Bair TL, Li P, Anderson JL:
Implementation of a computerized cardiovascular information system in
a private hospital setting. Am Heart J 1998, 136:792–803.
49. Anonymous: Myocardial infarction and mortality in the coronary artery
surgery study (CASS) randomized trial. N Engl J Med 1984, 310:750–758.
50. Kulkarni KR, Garber DW, Marcovina SM, Segrest JP: Quantification of
cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res
1994, 35:59–168.
May et al. Lipids in Health and Disease 2013, 12:55 Page 13 of 13
http://www.lipidworld.com/content/12/1/5551. Kulkarni KR, Tiwari H, Jones SR: A novel approach to measure
apolipoprotein A/apolipoprotein A1 ratio using the Vertical Auto Profile
method. Diab Vasc Dis Res 2007, 4:266.
52. Grundy SM, Brewer B, Cleeman JI, Smith SC, Lenfant C, for the Conference
Participants: Definition of the metabolic syndrome: report of the national
heart, lung, and blood institute/American heart association conference
on scientific issues related to definition. Circulation 2004, 109:433–438.
doi:10.1186/1476-511X-12-55
Cite this article as: May et al.: A new ratio for better predicting future
death/myocardial infarction than standard lipid measurements in
women >50 years undergoing coronary angiography: the
apolipoprotein A1 remnant ratio (Apo A1/ [VLDL3+IDL]). Lipids in Health
and Disease 2013 12:55.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
